June 22, 2016 7:28am
… In treating Duchenne Muscular Dystrophy?
Israel. The studies were conducted in conjunction with ADI, the Association Duchenne Israel, whose members are parents of children with Duchenne.
The Bottom Line: The studies demonstrated that, in a mouse model of muscular dystrophy, PLX-PAD cells reduced creatine phosphokinase (CPK), a marker of muscle degeneration or injury, by approximately 50% as compared to placebo.
PSTI closed at $1.21 which was DOWN -$0.07. The pre-market indication is +$0.10. Notice PSTI has been news quiet and is just rolling out more hyperbole to offset declines. Never lasts … pre- clinical mouse data is a disservice to those who deserve hope!
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. It is caused by a shortage of dystrophin, a protein that helps keep muscle fibers intact as they contract and relax. This shortage is due to a mutation in the gene that controls the production of dystrophin. Muscle weakness can begin as early as age 3, and by the early teens the heart and respiratory muscles also are affected. Average life expectancy for people with DMD is 27 years, though there is significant individual variability. Although girls can be carriers and mildly affected, the disease typically affects boys, and there is currently no cure.
